Why the study?
To assess individual variations in LDL-C response and investigate associations between baseline plasma surrogate markers of cholesterol metabolism and LDL-C reductions on combined lipid-lowering therapy.
Does atorvastatin and ezetimibe combination therapy reduce LDL-C consistently across different baseline cholesterol metabolism phenotypes in patients with STEMI?
Population
42 lipid-lowering therapy-naive STEMI patients
Comparison
Early combination therapy with atorvastatin 80 mg and ezetimibe 10 mg across quartiles of cholesterol metabolism markers
Design
Secondary analysis of a prospective cohort study
Follow-up
4-6 weeks
Key result
Upfront dual therapy with atorvastatin 80mg and ezetimibe 10mg achieved a median LDL-C reduction of 65.28% with no significant association between baseline cholesterol metabolism markers and treatment response.
Authors
Loading...
May support upfront dual statin-ezetimibe in STEMI for consistent LDL-C lowering; hypothesis-generating on independence from metabolism markers, needing RCT confirmation.
Cohort (n=42)
No
Does atorvastatin and ezetimibe combination therapy reduce LDL-C consistently across different baseline cholesterol metabolism phenotypes in patients with STEMI?
Upfront dual therapy with atorvastatin and ezetimibe in STEMI patients achieves robust LDL-C reduction with low interindividual variability, regardless of baseline cholesterol metabolism markers.
Makhmudova et al. (2026) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=42). Atorvastatin and ezetimibe was evaluated on LDL-C reduction from baseline. Upfront dual therapy with atorvastatin 80mg and ezetimibe 10mg achieved a median LDL-C reduction of 65.28% with no significant association between baseline cholesterol metabolism markers and treatment response.